Talazoparib, as a PARP inhibitor, has a clear contraindication population, mainly including patients with specific physiological states, organ dysfunction, and special constitutions. The following provides a detailed explanation of the population who are prohibited or need to use this medication with caution from six major aspects.

1. Pregnant women

(1) Absolute contraindication: May cause harm to the fetus, pregnancy status needs to be confirmed before treatment;

(2) Contraceptive requirements: Effective contraceptive measures must be taken during the treatment period and within 2 months after the last dose;

(3) Risk Warning: If pregnancy occurs during medication, the medication should be immediately discontinued and fetal risk assessed.

2. Breastfeeding women

(1) Prohibition of breastfeeding: Medications may affect infants through milk secretion;

(2) Discontinuation requirement: Breastfeeding can only be resumed 2 months after the last administration;

(3) Alternative solution: It is recommended to use formula milk powder for feeding.

3. Severe organ dysfunction

(1) Liver function: Lack of safety data for severe damage (total bilirubin>3 × ULN);

(2) Renal function: End stage renal disease (eGFR<15mL/min) should be used with caution;

(3) Hematotoxicity: Patients with baseline decreased blood cells need to be closely monitored.

4. Children and adolescents

(1) Safety and efficacy have not been established, and patients under 18 years old are prohibited from using it;

(2) In special circumstances, the risk return ratio needs to be evaluated by a specialist doctor.

5. History of drug allergies

(1) Prohibited for individuals allergic to PARP inhibitor components;

(2) Severe hypersensitivity reactions require permanent discontinuation of medication;

(3) Before taking medication, it is necessary to inquire in detail about the history of allergies.

6. Special genetic background

(1) The efficacy of BRCA wild-type patients is limited and requires confirmation through genetic testing;

(2) Certain genetic polymorphisms may lead to increased toxicity;

(3) It is recommended to undergo genetic counseling and testing before medication.